Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.
Finasteride and dutasteride, both 5-alpha reductase inhibitors, are considered first-line treatment for androgenetic hair loss in men and used increasingly in women. In each case, patients are expected to take the medications indefinitely despite the lack of research regarding long-term adverse effects. Concerns regarding the adverse effects of these medications has led the United States National Institutes of Health to add a link for post-finasteride syndrome to its Genetic and Rare Disease Information Center. Herein, the authors report the results of a literature search reviewing adverse events of 5-alpha reductase inhibitors as they relate to prostate cancer, psychological effects, sexual health, and use in women. Several large studies found no increase in incidence of prostate cancer, a possible increase of high-grade cancer when detected, and no change in survival rate with 5-alpha reductase inhibitor use. Currently, there is no direct link between 5-alpha reductase inhibitor use and depression; however, several small studies have led to depression being listed as a side effect on the medication packaging. Sexual effects including erectile dysfunction and decreased libido and ejaculate were reported in as many as 3.4 to 15.8 percent of men. To date, there are very few studies evaluating 5-alpha reductase inhibitor use in women. Risks include birth defects in male fetuses if used in pregnancy, decreased libido, headache, gastrointestinal discomfort, and isolated reports of changes in menstruation, acne, and dizziness. Overall, 5-alpha reductase inhibitors were well-tolerated in both men and women, but not without risk, highlighting the importance of patient education prior to treatment.
Dell Medical School, University of Texas at Austin, Austin, Texas;
Jason M
JM
Hirshburg
University of Texas Medical Branch, Galveston, Texa.
Petra A
PA
Kelsey
University of Texas Medical Branch, Galveston, Texa.
Chelsea A
CA
Therrien
Dell Medical School, University of Texas at Austin, Austin, Texas;
A Carlo
AC
Gavino
Dell Medical School, University of Texas at Austin, Austin, Texas;
Jason S
JS
Reichenberg
J Cosmet Dermatol. 2010 Dec;9(4):331-2
21122055
Gynecol Endocrinol. 2003 Feb;17 (1):57-63
12724020
J Sex Med. 2011 Jun;8(6):1747-53
21418145
J Investig Dermatol Symp Proc. 2005 Dec;10(3):184-9
16382660
Ann Pharmacother. 2010 Jun;44(6):1090-7
20442354
Prog Neurobiol. 2014 Feb;113:1-5
24121112
Am J Clin Exp Urol. 2014 Jul 12;2(2):136-44
25374915
Ann Dermatol. 2012 Aug;24(3):311-8
22879715
Steroids. 2010 Feb;75(2):109-53
19879888
World J Urol. 1997;15(1):21-6
9066090
J Clin Endocrinol Metab. 1994 Oct;79(4):1115-21
7962284
Front Endocrinol (Lausanne). 2011 Oct 05;2:38
22654805
Clin Ther. 1995 Sep-Oct;17(5):956-69
8595647
J Urol. 2006 Jan;175(1):217-20; discussion 220-1
16406915
N Engl J Med. 2013 Aug 15;369(7):603-10
23944298
J Clin Endocrinol Metab. 1994 Sep;79(3):831-5
8077369
N Engl J Med. 2010 Apr 1;362(13):1192-202
20357281
Exp Clin Endocrinol Diabetes. 1999;107(3):195-7
10376445
Gynecol Endocrinol. 1997 Aug;11(4):251-7
9272421
Pharmacotherapy. 2015 Jul;35(7):687-95
26133534
Urology. 2003 Mar;61(3):579-84
12639651
Drugs. 1999 Jan;57(1):111-26
9951956
Fertil Steril. 2003 Jan;79(1):91-5
12524069
J Eur Acad Dermatol Venereol. 2001 Sep;15(5):418-21
11763381
Pharmacopsychiatry. 2010 Jul;43(5):174-8
20486040
JAMA Intern Med. 2014 Aug;174(8):1301-7
24887392
J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89
9777765
Urology. 1994 Mar;43(3):284-92; discussion 292-4
7510911
Arch Dermatol. 2004 Jul;140(7):857-8
15262698
J Eur Acad Dermatol Venereol. 2011 Feb;25(2):211-4
20569283
Gynecol Endocrinol. 2007 Mar;23(3):142-5
17454167
J Clin Aesthet Dermatol. 2014 Dec;7(12):51-5
25584139
Br J Dermatol. 2003 Dec;149(6):1207-13
14674898
Asian J Androl. 2014 May-Jun;16(3):413-4
24625877
J Sex Med. 2008 Dec;5(12):2917-24
19090946
J Am Acad Dermatol. 2002 Nov;47(5):733-9
12399766
Urology. 2004 Apr;63(4):709-15
15072886
Acta Derm Venereol. 2004;84(6):488-9
15844649
Korean J Urol. 2014 Jun;55(6):367-79
24955220
Br J Dermatol. 2002 Oct;147(4):812-3
12366441
Nat Rev Cancer. 2001 Oct;1(1):34-45
11900250
J Clin Endocrinol Metab. 1995 Jan;80(1):233-8
7829618
Prostate. 2004 Dec 1;61(4):332-53
15389811
J Sex Med. 2007 Nov;4(6):1708-12
17655657
Neuropsychopharmacology. 2008 Dec;33(13):3146-56
18354385
BMC Clin Pharmacol. 2006 Oct 07;6:7
17026771
J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3
24411083
Urology. 1998 May;51(5):677-86
9610579
Fertil Steril. 2003 Apr;79(4):942-6
12749435
Arch Dermatol. 1999 Mar;135(3):257-8
10086445
N Engl J Med. 1996 Aug 22;335(8):533-9
8684407
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):451-61
17988775
Eur Urol. 2013 May;63(5):788-9; discussion 790-1
23305882
Fertil Steril. 2000 May;73(5):984-7
10785225
J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):768-76
11050579
N Engl J Med. 2003 Jul 17;349(3):215-24
12824459
Eur Urol. 2004 May;45(5):586-92; discussion 592
15082200
J Dermatol. 2002 Oct;29(10):665-9
12433001
Psychoneuroendocrinology. 2004 Sep;29(8):1071-81
15219659
Urology. 2002 Sep;60(3):434-41
12350480
Oncol Lett. 2014 Oct;8(4):1391-1396
25202340
CMAJ. 1996 Nov 1;155(9):1251-9
8911291
Int J Trichology. 2013 Jan;5(1):22-5
23960392
J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83
17848673
Rev Endocr Metab Disord. 2015 Sep;16(3):177-98
26296373
J Clin Psychiatry. 2012 Sep;73(9):1220-3
22939118
Fertil Steril. 1995 Aug;64(2):299-306
7615107
Rev Urol. 2005;7 Suppl 4:S31-41
16986053
N Engl J Med. 1992 Oct 22;327(17):1185-91
1383816
Indian J Dermatol Venereol Leprol. 2014 Nov-Dec;80(6):521-5
25382509
J Sex Med. 2011 Mar;8(3):872-84
21176115
J Clin Endocrinol Metab. 2004 May;89(5):2179-84
15126539